Infectious diseases represent Summit plc’s second core focus area and are a growing global health concern, based on the emergence of antibiotic-resistant bacteria and potential pandemic viral infections. Summit has considerable expertise and experience in developing therapeutics to treat infectious diseases, with key personnel having been heavily involved in advancing anti-viral products, including Epivir (lamivudine) and Relenza (zanamivir), from discovery through clinical development and onto the market.